- Home
- HL vs MRUS Comparison
HL vs MRUS Comparison
Compare HL & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- MRUS
- Stock Information
- Founded
- HL 1891
- MRUS 2003
- Country
- HL United States
- MRUS Netherlands
- Employees
- HL N/A
- MRUS N/A
- Industry
- HL Precious Metals
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HL Basic Materials
- MRUS Health Care
- Exchange
- HL Nasdaq
- MRUS Nasdaq
- Market Cap
- HL 3.9B
- MRUS 4.1B
- IPO Year
- HL N/A
- MRUS 2016
- Fundamental
- Price
- HL $7.69
- MRUS $66.83
- Analyst Decision
- HL Hold
- MRUS Strong Buy
- Analyst Count
- HL 5
- MRUS 12
- Target Price
- HL $7.60
- MRUS $91.00
- AVG Volume (30 Days)
- HL 21.4M
- MRUS 661.7K
- Earning Date
- HL 08-06-2025
- MRUS 08-05-2025
- Dividend Yield
- HL 0.20%
- MRUS N/A
- EPS Growth
- HL N/A
- MRUS N/A
- EPS
- HL 0.16
- MRUS N/A
- Revenue
- HL $1,060,106,000.00
- MRUS $56,228,000.00
- Revenue This Year
- HL $13.45
- MRUS $67.27
- Revenue Next Year
- HL $3.13
- MRUS $0.49
- P/E Ratio
- HL $48.37
- MRUS N/A
- Revenue Growth
- HL 36.30
- MRUS 59.77
- 52 Week Low
- HL $4.46
- MRUS $33.19
- 52 Week High
- HL $7.85
- MRUS $67.59
- Technical
- Relative Strength Index (RSI)
- HL 71.13
- MRUS 64.93
- Support Level
- HL $5.62
- MRUS $63.21
- Resistance Level
- HL $7.87
- MRUS $67.59
- Average True Range (ATR)
- HL 0.26
- MRUS 2.22
- MACD
- HL 0.15
- MRUS -0.27
- Stochastic Oscillator
- HL 87.75
- MRUS 97.33
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.